date,title,source
Oct-18-18,Zosano Pharma to Host Key Opinion Leader Meeting on New Treatments for Migraine and the Migraine Patients Perspective,GlobeNewswire
Oct-23-18,"Zosano Treats over 4,000 Migraines and Reaches an Important Goal in M207-ADAM Long-term Safety Study",GlobeNewswire
Oct-25-18,"Recent Analysis Shows Stellus Capital Investment, Nuance Communications, ProPetro Holding, Sanchez Energy, Granite Point Mortgage Trust, and Zosano Pharma Market Influences  Renewed Outlook, Key Drivers of Growth",GlobeNewswire
Nov-07-18,Zosano Pharma to Host Conference Call on Third Quarter 2018 Financial Results and Provide Operational Update,GlobeNewswire
Nov-14-18,Zosano Pharma Reports Third Quarter 2018 Financial Results and Operational Update,GlobeNewswire
Dec-12-18,Zosano Receives Conditional FDA Acceptance of Proposed Brand Name Qtrypta for M207,GlobeNewswire
Jan-16-19,"Zosano Appoints Linda Grais M.D., J.D. to Board of Directors",GlobeNewswire
Jan-31-19,Zosano Announces Publication of Positive Data on Qtryptas Potential as an Acute Treatment for Patients with Difficult-to-Treat Migraines,GlobeNewswire
